Gene patterns and risk prediction in hepatitis B liver failure
Part of Digestive system, Infections clinical trials.
This study looks at how gene changes (methylation) in people with hepatitis B-related liver failure may predict how well they will do. It aims to create a risk score to guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic hepatitis B (had the virus for more than 6 months).
- You have liver cirrhosis (scarring of the liver) caused by hepatitis B.
- You are currently in a sudden worsening of liver function (acute-on-chronic liver failure) with high bilirubin (over 85) and poor blood clotting (INR 1.5 or higher).
- You do not have other active hepatitis infections, liver cancer, or autoimmune liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at your risk of developing liver cancer if you have hepatitis B. It uses your medical history and test results to give you a better idea of your risk and help guide next steps.
This study is testing a new way to predict if people with chronic hepatitis B, who also have liver fibrosis or cirrhosis, might develop liver cancer (HCC). It uses your medical data to create a risk score, which could help you and your doctor plan earlier and more tailored monitoring.
This study looks at better ways to predict significant liver fibrosis (scarring) in people with chronic hepatitis B or non-alcoholic fatty liver disease. It aims to help avoid invasive tests like liver biopsy.
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
This study aims to predict the risk of developing liver cancer in people with chronic liver conditions such as hepatitis B or C, cirrhosis, or fatty liver disease. By participating, you may help researchers improve early detection and prevention strategies for liver cancer.
This study looks at a blood marker called HBV pgRNA to see if it can predict long-term outcomes for people with hepatitis B who are on antiviral therapy. It might help doctors better understand how well treatment is working.
Hear when a new HBV-related Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.